Abstract VEGFR, ERK and Abl had been respectively identified as good drug targets, and their crosstalk also had been well elaborated. Multitarget drugs were more advantageous for cancer treatment, however, no inhibitors simultaneously acting on the three proteins were developed due to their structural diversities. Herein, N-(4-((2-(2-(naphthaen-1-yl) acetamido) ethyl) carbamoyl) piperidin-4-yl)-6-(trifluoromethyl) nicotinamide (NEPT, 6a) was ...